nach oben

Rechtsmedizin

Erschienen in:

08.11.2022 | Multiple Sklerose | CME

Cannabidiol – berauschend unberauschend?

verfasst von: Prof. Dr. rer. nat. Dipl.-Math. Gisela Skopp, Matthias Graw, Frank Musshoff

Erschienen in: Rechtsmedizin | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Produkte, die Cannabidiol (CBD) enthalten, liegen derzeit hoch im Trend. Neben einer Anwendung als Begleitmedikation zu Clobazam bei therapieresistenten Epilepsieformen im Kindesalter gibt es derzeit nur wenige weitere Studien für einen therapeutischen Einsatz. CBD interagiert mit zahlreichen molekularen Zielstrukturen, während es eine vernachlässigbare Affinität gegenüber Cannabinoidrezeptoren zeigt. Die zahlreichen Darreichungsformen bestimmen v. a. die Bioverfügbarkeit und Nachweisbarkeitsdauer; eine ausreichende Zahl pharmakokinetischer Studien ist derzeit nicht verfügbar. Die bisher publizierten Methoden zur analytischen Erfassung von CBD schließen Tetrahydrocannabinol (THC), weitere Cannabinoide und Stoffwechselprodukte des THC ein. Die In-vivo-Zyklisierung des CBD zu THC ist ein bisher nicht gelöstes Problem. Während es für CBD-basierte Arzneimittel im Arzneibuch festgelegte analytische Prüfungsmethoden gibt, ist die Sicherheit CBD-haltiger Produkte in Bezug auf ihren THC-Gehalt für den Endverbraucher nicht gewährleistet. CBD-Blüten als Pflanzenteil der Gattung Cannabis unterliegen dem Betäubungsmittelgesetz. In Deutschland treffen für Zubereitungen mit CBD in isolierter Form die jeweiligen Bestimmungen oder Vorschriften, die sich aus der vom Hersteller angegebenen Verwendung ergeben, zu.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and ∆(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737–753PubMedCentralCrossRefPubMed

Chicca A, Schafroth MA, Reynoso-Moreno I, Erni R, Petrucci V, Carreira EM, Gertsch J (2018) Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high. Sci Adv. https://doi.org/10.1126/sciadv.aat2166CrossRefPubMedCentralPubMed

Geschwinde T (2013) Rauschdrogen. Marktformen und Wirkungsweisen, 7. Aufl. Springer, Berlin, HeidelbergCrossRef

Schweizerische Eidgenossenschaft (2017) Produkte mit Cannabidiol (CBD). Überblick und Vollzugshilfe

Mechoulam R, Shvo Y (1963) Hashish. I. The structure of cannabidiol. Tetrahedron 19:2073–2078CrossRefPubMed

Ujvary I, Hanus L (2016) Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res 1:90–101PubMedCentralCrossRefPubMed

Baek SH, Srebnik M, Mechoulam R (1985) Borontrifluoride on alumina/a modified Lewis acid reagent. An improved synthesis of cannabidiol. Tetrahedron Lett 26:1083–1086CrossRef

GW Pharma Limited (2004) Patent GB 2 393 182 A. Substantially pure cannabidiol and a method obtaining it from plant material. Salesbury

Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, ∆⁹-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 168:657–690CrossRef

10.

Bih CI, Chen T, Nunn AVM, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12:699–730CrossRef

11.

Martínez V, De-Hond AI, Borrelli F, Capasso R, Del Castillo MD, Abalo R (2020) Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: useful nutraceuticals? Molecules. https://doi.org/10.3390/ijms21093067CrossRefPubMedCentralPubMed

12.

Millar SA, Stone NL, Yates AS, O’Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365. https://doi.org/10.3389/fpharm.2018.01365CrossRefPubMedCentralPubMed

13.

Lucas CL, Galettis P, Schneider J (2018) The pharmacokinetics and pharmacodynamics of cannabinoids. Br J Clin Pharmacol 84:2477–2482PubMedCentralCrossRefPubMed

14.

Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF (2013) A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QT study to evaluate the electrophysiologic effects of THC/CBD spray. Clin Pharmacol Drug Dev 2:285–294CrossRefPubMed

15.

Stott CG, White L, Wright S, Wilbraham D, Guy GW (2013) A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol 69:825–834CrossRefPubMed

16.

Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 32:1053–1067PubMedCentralCrossRefPubMed

17.

Cherniakov I, Izgelov D, Domb AJ, Hoffman A (2017) The effect of ProNanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci 109:21–30CrossRefPubMed

18.

Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 132:77–83CrossRef

19.

Guy GW, Robson PJ (2004) A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on three different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 3:79–120CrossRef

20.

Wheless JW, Dlugos D, Miller I, Oh DA, Parikh N, Phillips S, Renfroe JB, Roberts CM, Saeed I, Sparagana SP, Yu J (2019) Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs 33:593–604PubMedCentralCrossRefPubMed

21.

Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303–320CrossRefPubMed

22.

Kraemer M, Broecker S, Madea B, Hess C (2019) Decarbonylation: a metabolic pathway of cannabidiol in humans. Drug Test Anal 11:957–967CrossRefPubMed

23.

Bergamaschi MM, Barnes A, Queiroz RHC, Hurd YL, Huestis MA (2013) Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem 405:4679–4468PubMedCentralCrossRefPubMed

24.

Wertlake PT, Henson MD (2016) A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana. J Pain Res 9:81–85PubMedCentralCrossRefPubMed

25.

Pérez-Acevedo AP, Busardò FP, Pacifici R, Mannocchi G, Gottardi M, Poyatos L, Papaseit E, Pérez-Mañá C, Martin S, Di Trana A, Pichini S, Farré M (2020) Disposition of cannabidiol metabolites in serum and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. Pharmaceuticals 13:459. https://doi.org/10.3390/ph13120459CrossRefPubMedCentralPubMed

26.

Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM (2005) Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 27:799–810CrossRefPubMed

27.

Brown JD, Winterstein AG (2019) Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 8:989. https://doi.org/10.3390/jcm8070989CrossRefPubMedCentralPubMed

28.

Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L (1981) Interactions of D1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37:1090–1092CrossRefPubMed

29.

Desrosiers NA, Lee D, Concheiro-Guisan M, Scheidweiler KB, Gorelick DA, Huestis MA (2014) Urinary cannabinoid disposition in occasional and frequent smokers: Is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? Clin Chem 60:361–372CrossRefPubMed

30.

Wei B, Wang L, Blount BC (2015) Analysis of cannabinoids and their metabolites in human urine. Anal Chem 87:10183–10187PubMedCentralCrossRefPubMed

31.

Andersson M, Scheidweiler KB, Sempio C, Barnes A, Huestis MA (2016) Simultaneous quantification of eleven cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX‑S strips. Anal Bioanal Chem 2016:6461–6471CrossRef

32.

Sempio C, Scheidweiler KB, Barnes AJ, Huestis MA (2018) Optimization of recombinant β‑glucuronidase hydrolysis and quantification of eight urinary cannabinoids andmetabolites by liquid chromatography tandem mass spectrometry. Drug Test Anal 10:518–529CrossRefPubMed

33.

Schwope DM, Karschner EL, Gorelick DA, Huestis MA (2011) Identification of recent cannabis use: whole-blood and plasma free and glucuroniated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 57:1406–1414PubMedCentralCrossRefPubMed

34.

Andrenyak DM, Moody DE, Slawson MH, O’Leary DS, Haney M (2017) Determination of ∆‑9-tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and cannabidiol in human plasma using gas chromatography-tandem mass spectrometry. J Anal Toxicol 41:277–288PubMedCentralPubMed

35.

Skopp G, Strohbeck-Kühner P, Mann K, Hermann D (2007) Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int 170:46–50CrossRefPubMed

36.

Kieliba T, Lerch O, Andresen-Streichert H, Rothschild MA, Beike J (2019) Simultaneous quantification of THC-COOH, OH-THC, and further cannabinoids in human hair by gas chromatography-tandem mass spectrometry with electron ionization applying automated sample preparation. Drug Test Anal 11:267–278CrossRefPubMed

37.

Andrews R, Paterson S (2012) Production of identical retention times and mass spectra for D9-tetrahydrocannabinol and cannabidiol following derivatization with trifluoracetic anhydride with 1,1,1,3,3,3-hexafluoroisopropanol. J Anal Toxicol 36:61–65CrossRefPubMed

38.

Skopp G, Pötsch L (2004) An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol 28:35–40CrossRefPubMed

39.

Paul R, Williams R, Hodson V, Peake C (2019) Detection of cannabinoids in hair after cosmetic application of hemp oil. Sci Rep 9:2582. https://doi.org/10.1038/s41598-019-39609-0CrossRefPubMedCentralPubMed

40.

Grotenhermen F, Ruso E, Zuardi AW (2017) Even high doses of oral cannabidiol do not cause THC-like effects in humans: comment on Merrick et al. Cannabis Cannabinoid Res 2(1):1–4PubMedCentralCrossRefPubMed

41.

Golombek P, Müller M, Barthlott I, Sproll C, Lachenmeier DW (2020) Conversion of cannabidiol (CBD) into psychotropic cannabinoids including tetrahydrocannabinol (THC): a controversy in the scientific literature. Toxics 8:41. https://doi.org/10.3390/toxics8020041CrossRefPubMedCentralPubMed

42.

Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram A (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40:701–708CrossRefPubMed

43.

Watanabe K, Itokawa Y, Yamaori S, Funahashi T, Kimura T, Kaji T, Usami N, Yamamoto I (2007) Conversion of cannabidiol to ∆⁹-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Forensic Toxicol 25:16–21CrossRef

44.

Deutsches Arzneibuch (2020) 9. Aufl. Apothekerverlag, Stuttgart. ISBN 978-3-7692-7552‑0

45.

Hädener M, Gelmi TJ, Martin-Fabritius M, Weinmann W, Pfäffli M (2019) Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a “tobacco substitute”. Int J Legal Med 133:821–832CrossRefPubMed

46.

Bonn-Miller M, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R (2017) Labeling accuracy of cannabidiol extracts sold online. J Am Med Assoc 7:1708–1709CrossRef

47.

Giroud C, de Cesare M, Berthet A, Varlet V, Concha-Lozano N, Favrat B (2015) E‑cigarettes: a review of new trends in cannabis use. Int J Environ Res Public Health 12:9988–10008PubMedCentralCrossRefPubMed

48.

Meng Q, Buchanan B, Zuccolo J, Poulin MM, Gabriele J, Baranowski DC (2018) A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products. PLoS ONE 13:e196396. https://doi.org/10.1371/journal.pone.0196396CrossRefPubMedCentralPubMed

49.

FDA News Release (2020) FDA approves new indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic disease

50.

Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E (2019) Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials. Molecules 24:1459. https://doi.org/10.3390/molecules24081459CrossRefPubMedCentralPubMed

51.

Pauli CS, Conroy M, Vanden Heuvel BD, Park SH (2020) Cannabidiol drugs clinical trial outcomes and adverse effects. Front Pharmacol 11:63. https://doi.org/10.3389/fphar.2020.00063CrossRefPubMedCentralPubMed

52.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088–1098CrossRefPubMed

53.

Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O’Sullivan SE (2019) Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo. A randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis 25:1006–1018CrossRefPubMed

54.

McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225–231CrossRefPubMed

55.

Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, Bloomfield MAP, O’Ryan D, Kinghorn J, Morgan CJA, Mofeez A, Curran HV (2020) Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 7:865–874PubMedCentralCrossRefPubMed

56.

Corron J, Phillips JA (2018) A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 3:152–161CrossRef

57.

Arkell TR, Vinckenbosch F, Kevin RC, Theunissen L, McGregor IS, Raemakers JG (2020) Effect of cannabidiol and ∆⁹-terahydrocannabinol on driving performance. A randomized clinical study. JAMA 324:2177–2186PubMedCentralCrossRefPubMed

58.

Deutscher Arzneimittel-Codex® (2019) Neues Rezeptur-Formularium® (DAC/NRF) Ergänzungsbuch zum Arzneibuch inkl. 2/2020. Deutscher Apothekerverlag, Stuttgart. ISBN 978-3-7741-0044‑2.

59.

Lachenmeier DW, Diel P (2019) A warning against the negligent use of cannabidiol in professional and amateur athletes. Sports 7:251. https://doi.org/10.3390/sports7120251CrossRefPubMedCentralPubMed

60.

Lachenmeier DW, Bock V, Deych A, Sproll C, Rajcic de Rezende T, Walch SG (2019) Hanfhaltige Lebensmittel – ein Update. Dtsch Lebensmitt Rundsch 115:351–372

61.

Meier U, Dussy F, Scheurer E, Mercer-Chalmers-Bender K, Hangartner S (2018) Cannabinoid concentrations in blood and urine after smoking cannabidiol joints. Forensic Sci Int 291:62–67CrossRefPubMed

Titel: Cannabidiol – berauschend unberauschend?
verfasst von: Prof. Dr. rer. nat. Dipl.-Math. Gisela Skopp
Matthias Graw
Frank Musshoff
Publikationsdatum: 08.11.2022
Verlag: Springer Medizin
Schlagwörter: Multiple Sklerose
Cannabinoide
Pharmakodynamik
Pharmakokinetik
Clobazam
Erschienen in: Rechtsmedizin / Ausgabe 6/2022
Print ISSN: 0937-9819
Elektronische ISSN: 1434-5196
DOI: https://doi.org/10.1007/s00194-022-00595-9

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Fatal bleeding following left internal jugular vein cannulation associated with type A1 endoleak, false aneurysm and aortobronchopulmonary fistula

Untersuchungen zum Einfluss verschiedener Mund-Nase-Schutzmasken auf die beweissichere Atemalkoholmessung

Mitteilungen der Deutschen Gesellschaft für Rechtsmedizin

Medizinische Versorgung von Menschen mit Foltererfahrung: Trainings zu Folter(folgen) sind wichtig; strukturelle Herausforderungen sind ungelöst

Manner of death, causes of death and autopsies in infants, children and adolescents

Modification of the examination of fitness for custody as a result of external factors in the period 2013–2018